Vasomedical, Inc. - EECP® Therapy | Home

What's New

Vasomedical Announces Strong Revenue Growth for the Three Months Ended March 31, 2012

Advanced Heart Disease Patient Regains Lost Energy, Attends 50-Year Class Reunion After Receiving EECP® Therapy at Heart House in Washington Township

Vasomedical Successfully Exhibited at the 61st Annual Scientific Sessions of the American College of Cardiology

Vasomedical Announces Record Operating Income of $5.2 Million and 169% Increase in Revenue for the Seven Months Ended December 31, 2011

Florida Cardiologist Tells Angina Patients, “Don’t Give Up Hope: Non-Invasive EECP® Therapy Can Relieve Chest Pain when Stents and Bypasses Do Not”

Newsletter Archive


	EECP Newsletter - Volume 4, Issue 1 Highlights A Comparison Of Enhanced External Counterpulsation (EECP®) Therapy with Ranolazine (Ranexa®) for the Treatment of Refractory Angina FDA 510(k) Clearance on Four New Ambulatory Monitoring Devices Reimbursement update

	EECP Newsletter - Volume 3, Issue 1 Highlights Learn about the results of randomized controlled studies in EECP® The EECP® Therapy iPhone application Reimbursement update

	EECP Newsletter - Volume 2, Issue 2 Highlights Learn about how EECP can treat heart failure, billing for EECP and its cost-effectiveness Vasomedical unveils new patient management products at AHA

	EECP Newsletter - Volume 2, Issue 1 Highlights Learn how your patients can benefit from a repeat course of EECP® treatment Vasomedical receives FDA 510(k) clearance for holter monitoring products

	EECP Newsletter - Volume 1, Issue 1 Highlights Cardiac syndrome X patients may benefit from EECP® therapy